Access Official Technical PDF

Share Summary:LinkedInEmail

The 2019 outlook for chemical industry M&A reflected a market shaped by available financing, demand for specialty businesses and strategic portfolio changes. Transactions announced during the first half of the year ranged from specialty surfactants and electronic materials to large industrial materials businesses. For manufacturers, plant managers and automation leaders, these corporate moves provide context for understanding how ownership, investment priorities and industry structure were changing at the time.

The figures and deal announcements discussed here are historical, drawn from a market update covering activity through June 2019. They should be read as a snapshot of that period rather than a current market assessment.

What supported chemical industry M&A in 2019?

Market commentary in the update described capital markets as having recovered after high-yield spreads widened in December and January amid concern about a broader correction. By June, financing conditions were characterized as healthy, with debt availability supporting robust transaction multiples in some specialty chemical segments. Financial sponsors and strategic buyers were both competing for assets, making the outcome of individual sale processes difficult to predict.

Specialty chemicals attracted particular interest. One market participant cited valuations of 11 to 14 times EBITDA in certain specialty segments. That range was not presented as a sector-wide average; rather, it illustrated that some businesses continued to command high valuations despite volatility in public equities.

The distinction matters because the chemical sector is diverse. A specialty formulation business, a basic chemicals producer and a distributor can have different market exposures and financial profiles. The public-company data in the update likewise showed varied enterprise-value-to-EBITDA multiples across categories, including basic and diversified chemicals, specialty companies and distributors.

Portfolio changes and strategic dealmaking

Several announced transactions showed companies using acquisitions and divestitures to reshape their portfolios. In March 2019, Evonik agreed to sell its methacrylates business to Advent International for an enterprise value of €3 billion, reported as 8.5 times EBITDA. Evonik said the divestiture was part of a strategy to sharpen its focus on specialty chemicals and that proceeds would support its balance sheet and targeted growth projects.

Other transactions reflected interest in businesses with differentiated technologies or end-market exposure:

  • Arkema and ArrMaz: Arkema agreed to acquire the specialty surfactants company for an enterprise value of $570 million. ArrMaz served crop nutrition, mining and infrastructure markets. Arkema said the deal would combine complementary formulation expertise, technologies and geographic reach.
  • Merck KGaA and Versum Materials: Merck agreed to acquire Versum for $6.5 billion, positioning the combination to expand Merck’s electronic materials business serving semiconductor and display industries.
  • Parker Hannifin and LORD Corporation: Parker Hannifin announced a cash acquisition valued at about $3.68 billion. LORD supplied adhesives, coatings, vibration and motion-control technologies for aerospace, automotive and industrial markets.

Together, these deals illustrate different strategic rationales: concentrating a portfolio, adding specialized materials capabilities, and increasing exposure to selected industrial or technology markets. They do not imply a single acquisition playbook for chemical companies.

Cross-border considerations and market uncertainty

Deal activity also faced regulatory and geographic constraints. Commentary in the update noted that Chinese companies encountered difficulty completing some transactions, citing U.S. national-security reviews by the Committee on Foreign Investment in the United States (CFIUS) and restrictions on moving capital out of China. The same commentary distinguished these challenges from activity by Japanese buyers, which were described as active in the United States.

A potential Chevron Phillips Chemical bid for Nova Chemicals was reported in June 2019, but the source material described it as a possible transaction, not a completed acquisition. The report suggested that a deal could alter the combined companies’ positions in polyethylene and merchant ethylene. It also noted that another bidder could emerge or that Nova’s owner might retain a stake. Such distinctions are important when interpreting deal headlines: announced interest, signed agreements and completed transactions represent different stages of a process.

Signals to watch beyond transaction headlines

The update pointed to the high-yield debt market as an indicator to monitor for a more consequential downturn. Volatility in public equities alone was not considered conclusive; concern would increase if broader market pressures reached high-yield credit, potentially reducing liquidity. For businesses evaluating acquisitions or investment plans, financing conditions can affect both buyers’ capacity to transact and sellers’ ability to achieve expected valuations.

Commodity and macroeconomic indicators provide additional context. The update tracked weekly prices for inputs including crude oil, ethylene, propylene, butadiene, benzene, mixed xylene, toluene and natural gas. It also included U.S. automotive sales, housing starts, GDP growth, consumer prices, chemical railcar loadings and the Chemicals Activity Barometer. These indicators help frame the demand and cost environment, but the charts do not by themselves establish the cause of any individual company’s performance or deal valuation.

Practical implications for chemical businesses

For technical decision-makers, M&A is relevant not only as a financial event but also as a possible precursor to changes in ownership, portfolio priorities and investment direction. The 2019 transactions show why it is useful to track:

  • Business mix: whether a company is emphasizing specialty products, divesting selected operations or expanding into adjacent markets.
  • Deal status: whether a transaction is rumored, agreed, subject to regulatory approval or closed.
  • Financing conditions: how credit availability may influence deal activity and valuations.
  • Operating context: how input prices and end-market indicators relate to the markets served by a business.

For plant and operations leaders, these are contextual signals, not a basis for assuming that a specific acquisition will change site-level plans. The practical step is to distinguish verified company announcements from market speculation and assess any confirmed changes through the relevant business and operational channels.

Conclusion

The first half of 2019 offered a clear example of how financing, specialty-market interest, portfolio strategy and regulatory conditions can intersect in chemical industry M&A. High valuations in selected specialty segments coexisted with broader market uncertainty, while major transactions pursued different strategic objectives. Following deal status, credit-market conditions and relevant sector indicators can help industrial decision-makers interpret corporate changes without confusing market signals with confirmed operational impacts.

Access Official Technical PDF

About The Author